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Monitoring antiviral resistance in patients receiving
nucleos(t)ide analog therapies for hepatitis B:
Which method should be used?q
Bulent Degertekin, Anna S. Lok*
Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109, USASee Article, pages 895–902Antiviral drug resistance is a major hurdle to the suc-
cess of nucleos(t)ide analog therapy for hepatitis B.
Among nucleoside-naı¨ve patients, antiviral drug resis-
tance had been reported in up to 70% of patients after
4 years of lamivudine (LVD), 29% after 5 years of ade-
fovir, 1% after 4 years of entecavir (ETV), and 9–22%
after 2 years of telbivudine [1–4]. Resistance rates are
substantially higher in patients with prior resistance to
LVD, with rates of up to 20% after 2 years of adefovir
and 40% after 4 years of entecavir [3,5]. Sequential ther-
apy had also been reported to result in the selection of
multi-drug resistant HBV [6,7].
A fundamental issue regarding antiviral resistance is
the criteria for deﬁning drug-resistant mutations and
the method used to diagnose drug resistance [8]. In clin-
ical practice, virologic breakthrough (deﬁned as a
greater than 1 log increase in serum hepatitis B virus
[HBV] DNA from nadir during treatment) is often the
only method used to diagnose drug resistance. However,
breakthroughs are not always due to drug resistance.
Clinical trials found that 30–50% of patients with viro-
logic breakthroughs had no detectable antiviral drug-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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E-mail address: aslok@umich.edu (A.S. Lok).resistant mutations indicating that non-adherence may
be the reason for the breakthroughs [9–13]. Empiric
modiﬁcation of treatment based on presumed diagnosis
of drug resistance may unnecessarily expose patients to
sequential therapies and eventually exhaust all available
treatments.
On the other hand, failure to detect antiviral drug-
resistant mutations does not exclude the possibility that
breakthrough was related to drug resistance. Drug-resis-
tant mutations may be present but were not detected due
to lack of sensitivity of the method used. Direct (or pop-
ulation) sequencing of PCR-ampliﬁed HBV DNA is the
most common method used for detecting antiviral drug-
resistant mutations but these mutations need to reach
approximately 20% of the total HBV quasispecies pool
to be detected. Restriction fragment length polymor-
phism (RFLP) analyses and reverse hybridization assay
(line probe, LiPA DR) are more sensitive and can detect
drug-resistant mutations that comprise 5% of the total
viral population [14–17]. However, these assays can only
detect a limited number of previously characterized
mutations. Furthermore, RFLP analysis may not be
possible for all resistant mutations as endonucleases spe-
ciﬁc for such sequences may not exist. Mutations may be
missed because they are not captured by the assay e.g.
mutations located outside the reverse transcriptase
(RT) domain of the HBV polymerase gene and muta-
tions not detected by any of the probes in the line probe
assay. In this regard, sequencing using microchip-based
technology using oligonucleotide microarrays has the
advantage that the entire viral genome can be scannedPublished by Elsevier B.V. All rights reserved.
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recognized if they have not been reported previously;
this would particularly be diﬃcult if baseline HBV
sequences were not available for comparison. As an
increasing number of patients with divergent HBV
sequences are exposed to nucleos(t)ide analog treat-
ments, additional mutations in the reverse transcriptase
domain other than the signature resistance mutations
may be identiﬁed, e.g. alanine to threonine substitution
at position 181 (rtA181T) [19] and methionine to serine
substitution at position 204 (rtM204S) [20] had been
reported to be associated with LVD resistance in addi-
tion to methionine to valine or isoleucine substitution
at position 204 (rtM204V/I).
Caution must be exercised in attributing changes in
the HBV RT domain as the cause of antiviral drug resis-
tance. The signiﬁcance of several mutations such as
rtA181T and secondary resistance to adefovir [21,22],
rtI233V and primary resistance to adefovir [23,24] and
rtA194T and secondary resistance to tenofovir [25,26]
remain controversial. Thus, phenotypic assays are neces-
sary to conﬁrm that a newly identiﬁed mutation(s) is
associated with drug resistance and to deﬁne the spec-
trum of mutations associated with resistance to new
therapies.
In this issue of the Journal, Baldick et al. present a
comprehensive phenotypic analysis of 511 patient iso-
lates collected from clinical trials of ETV therapy in
nucleoside-naı¨ve and in LVD-refractory hepatitis B
patients [27]. In previous studies, the authors demon-
strated that mutations associated with resistance to
LVD decrease susceptibility to ETV by 8-fold and addi-
tion of mutations at rtT184, S202, and M250 further
decrease susceptibility to ETV by approximately 10-fold
[28]. In the current study, the authors ﬁrst investigated
the correlation between genotypic resistance and ETV
susceptibility using laboratory clones. Then, they
repeated the same studies using patient-derived clones.
The authors found that laboratory clones with rtM204V
and rtL180M substitutions displayed 8-fold reduced
ETV susceptibility, and addition of rtT184L, rtS202G
or rtM250V substitutions further reduces ETV suscepti-
bility by approximately 100-fold relative to wild-type
HBV. They also showed that patient isolates displayed
a similar relationship between genotypic and phenotypic
resistance as compared to laboratory clones although
the variability in ETV susceptibility was greater with
patient derived clones. These ﬁndings are important as
phenotypic assays are time-consuming [8,29]. That the
same results can be obtained by introducing a variety
of mutations to laboratory clones versus creating sepa-
rate clones derived from individual patient isolates
enable phenotypic conﬁrmation of newly identiﬁed
putative drug-resistant mutations to be performed more
expeditiously. The authors noted that while the results
of individual patient clones generally correlated with‘population phenotyping’ in which the entire patient iso-
late quasispecies is cloned en masse to mimic the circu-
lating virus pool, a decrease in ETV susceptibility was
observed only when clones with ETV-resistant muta-
tions approach 25% of the virus population.
Previous reports from these authors [28,30] and some
sections of the current paper indicated that the back-
bone for ETV resistance is a combination of rtL180M
and rtM204V. However, data in this current study
clearly showed that rtM204I alone has the same eﬀect
(Figs. 1B and 2, and Table 2). Clariﬁcation of this point
is important as patients with telbivudine resistance
which is associated with rtM204I but not rtM204V
[31] would also have diminished response to ETV and
increased risk of ETV resistance.
The authors observed a range in ETV resistance in
the phenotypic studies with rtS202G/C substitutions,
some rtT184 substitutions, and multiple ETV resistance
substitutions being associated with the highest level of
resistance. These data need to be veriﬁed as only 1 or
2 clones from patient isolates were tested for some sub-
stitutions. Until further data are available, all the
reported substitutions including those involving
rtM250 should be considered to be associated with
ETV resistance.
An important contribution of Baldick et al.’s study is
the careful analysis of isolates frompatientswith virologic
breakthrough but no detectable substitutions at rt184,
202 and 250. The authors performed phenotypic studies
using full-length patient isolates and recombinants cre-
ated with the patients’ RT domain obtained at the time
of virologic breakthrough and found similar ETV suscep-
tibility as wild-type HBV clones as well as isolates from
these patients obtained at baseline. By contrast, studies
using isolates from patients with LVD or ETV resistance
substitutions showed the expected ETV susceptibility
proﬁles whether patient RT or full-length virus sequence
was used. These data indicate that virologic breakthrough
in patients with no detectable substitutions at rt184, 202
and 250 is likely related to non-compliance with medica-
tions and not to unidentiﬁedmutations in the RT domain
or elsewhere in the HBV genome.
How would the results of this study inﬂuence antivi-
ral resistance monitoring of hepatitis B patients receiv-
ing nucleos(t)ide analog therapies? Serum HBV DNA
monitoring to detect virologic breakthrough remains
the most practical method in clinical practice. Testing
for genotypic resistance should be performed in patients
with virologic breakthrough. Treatment should be mod-
iﬁed in patients found to have signature resistance muta-
tions. Medication compliance should be reinforced in
patients with no detectable resistance mutations. Addi-
tional testing using more sensitive methods for geno-
typic resistance may be performed. Alternatively,
genotypic resistance can be repeated in patients with
persistent virologic breakthrough despite medication
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had not been reported to be associated with resistance
to the antiviral drug administered should be tested in
phenotypic assays. Laboratory strains with the identi-
ﬁed substitutions introduced by site directed mutagene-
sis would suﬃce in most instances but conﬁrmation of
phenotypic resistance using selected patient isolates
should still be performed when evaluating resistance to
new antiviral drugs. Only substitutions shown to reduce
susceptibility in carefully conducted phenotypic studies
should be reported as resistance-associated mutations.
These recommendations are in line with those of an
international panel [8].
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